Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective

Interstitial lung diseases (ILDs) are a large and diverse group of rare and chronic respiratory disorders, with idiopathic pulmonary fibrosis (IPF) being the most common and best-studied member. Increasing interest in fibrosis as a therapeutic target and the appreciation that fibrotic mechanisms may...

Full description

Bibliographic Details
Published in:	Biomedicines
Main Authors:	Carlo Albera, Giulia Verri, Federico Sciarrone, Elena Sitia, Mauro Mangiapia, Paolo Solidoro
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Subjects:	antifibrotic therapy fibrosis idiopathic pulmonary fibrosis interstitial lung disease nintedanib pirfenidone
Online Access:	https://www.mdpi.com/2227-9059/9/9/1237

Similar Items

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
by: Fabio Perrotta, et al.
Published: (2024-06-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
by: Hironao Hozumi, et al.
Published: (2024-07-01)

Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study
by: Francesca Lalla, et al.
Published: (2025-10-01)

Nintedanib in chronic fibrosing interstitial lung diseases. A case series
by: Raquel García Sevila, et al.
Published: (2024-04-01)

Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention
by: Vito D’Agnano, et al.
Published: (2024-02-01)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01)

The Role of Antifibrotic Therapy in Pulmonary Fibrosis and Lung Cancer: A Multicenter Retrospective Analysis
by: Francesco Rocco Bertuccio, et al.
Published: (2025-09-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
by: Sebastian Majewski, et al.
Published: (2025-06-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
by: Stefano Levra, et al.
Published: (2022-12-01)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
by: Carla R. Copeland, et al.
Published: (2021-10-01)

Pulmonary fibrosis: New horizons and clinical solutions: A review II Expert Council “Idiopathic pulmonary fibrosis and progressive pulmonary fibroses. Real Practice” Symposium Review October 26, 2024, Sochi, Russia
by: Sergey N. Avdeev, et al.
Published: (2025-01-01)

Historical eye on IPF: a cohort study redefining the mortality scenario
by: Sara Tomassetti, et al.
Published: (2023-06-01)

Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?
by: Karol Bączek, et al.
Published: (2024-08-01)

The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry
by: Cathryn T. Lee, et al.
Published: (2024-06-01)

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
by: Stefano Kette, et al.
Published: (2025-03-01)

A clinical case of idiopathic pulmonary fibrosis against the background of comorbid pathology
by: A. V. Teteneva, et al.
Published: (2021-10-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01)

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024-05-01)

Pulmonary Hypertension-Related Interstitial Lung Disease: An Expert Opinion with a Real-World Approach
by: Rachel N. Criner, et al.
Published: (2025-03-01)

Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy
by: N. A. Kuzubova, et al.
Published: (2020-11-01)

The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
by: Michał Żuber, et al.
Published: (2024-06-01)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
by: Timothy M. Dempsey, et al.
Published: (2022-01-01)

Idiopathic pulmonary fibrosis: a clinical case of long-term follow-up
by: Galina L. Ignatova, et al.
Published: (2022-09-01)

Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype
by: L. P. Ananieva, et al.
Published: (2021-01-01)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
by: Paolo Cameli, et al.
Published: (2022-08-01)

Interstitial lung diseases: a view on the problem
by: O. G. Sych, et al.
Published: (2025-06-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

INTERSTITIAL LUNG DISEASES: KEY TARGETS FOR THERAPY
by: N. A. Shostak, et al.
Published: (2018-06-01)

Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2024-02-01)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
by: David A. Scott, et al.
Published: (2019-08-01)

The Management of Patients With Idiopathic Pulmonary Fibrosis
by: Paolo Spagnolo, et al.
Published: (2018-07-01)

The Role of Nintedanib in the Treatment of Progressive Pulmonary Fibrosis of Autoimmune-Related Interstitial Lung Disease
by: Aulia Rahman Ardan, et al.
Published: (2023-11-01)

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
by: Vinod K. Viswanathan, et al.
Published: (2024-09-01)